We at Gongwin Biopharm Co., Ltd are researching and developing an innovative ‘Minimally Invasive Targeted Tumor Ablation’ technique for treating focal malignancies. Our proprietary core technology is intra-tumoral injection of PTS (Para Toluene Sulfonamide) by combining the active therapeutic agent and following minimally invasive intervention techniques, which is unique and distinct from traditional anti-tumor therapies that are being opted by medical professionals. Core benefits for patients: Targeted selectivity – Onset within 24hours of injection & almost no damage to adjacent tissue. Broader Efficacy – Application in head & neck, breast, lung, liver & other cancer types. Safety – No severe systemic toxicities.